Epidemiology and pathogenesis of maternal-fetal transmission of Trypanosoma cruzi and a case for vaccine development against congenital Chagas disease

Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165591. doi: 10.1016/j.bbadis.2019.165591. Epub 2019 Oct 31.

Abstract

Trypanos o ma cruzi (T. cruzi or Tc) is the causative agent of Chagas disease (CD). It is common for patients to suffer from non-specific symptoms or be clinically asymptomatic with acute and chronic conditions acquired through various routes of transmission. The expecting women and their fetuses are vulnerable to congenital transmission of Tc. Pregnant women face formidable health challenges because the frontline antiparasitic drugs, benznidazole and nifurtimox, are contraindicated during pregnancy. However, it is worthwhile to highlight that newborns can be cured if they are diagnosed and given treatment in a timely manner. In this review, we discuss the pathogenesis of maternal-fetal transmission of Tc and provide a justification for the investment in the development of vaccines against congenital CD.

Keywords: Chagas; Congenital; Maternal-fetal transmission; Trypanosoma cruzi; Vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Chagas Disease / immunology*
  • Chagas Disease / parasitology
  • Chagas Disease / pathology*
  • Female
  • Fetus / immunology
  • Fetus / parasitology
  • Fetus / pathology
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Pregnancy
  • Trypanosoma cruzi / immunology*
  • Vaccines / immunology*

Substances

  • Vaccines